Checkpoint Therapeutics (NASDAQ:CKPT) Price Target Raised to $7.00

Checkpoint Therapeutics (NASDAQ:CKPT - Free Report) had its price objective lifted by Lake Street Capital from $4.00 to $7.00 in a research report sent to investors on Monday,Benzinga reports. Lake Street Capital currently has a buy rating on the stock.

Separately, HC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of Checkpoint Therapeutics in a research report on Monday.

Checkpoint Therapeutics Stock Down 7.6 %

Shares of NASDAQ:CKPT traded down $0.28 during midday trading on Monday, reaching $3.39. The company had a trading volume of 16,432,481 shares, compared to its average volume of 623,646. Checkpoint Therapeutics has a 1-year low of $1.36 and a 1-year high of $4.50. The stock has a market cap of $165.53 million, a PE ratio of -1.83 and a beta of 1.34. The business's 50 day moving average price is $3.48 and its 200 day moving average price is $2.66.

Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.08). On average, research analysts expect that Checkpoint Therapeutics will post -0.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Checkpoint Therapeutics

Large investors have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new stake in Checkpoint Therapeutics in the third quarter valued at approximately $30,000. XTX Topco Ltd bought a new stake in shares of Checkpoint Therapeutics during the second quarter worth about $34,000. Gladstone Institutional Advisory LLC lifted its position in Checkpoint Therapeutics by 141.4% in the 3rd quarter. Gladstone Institutional Advisory LLC now owns 35,000 shares of the company's stock valued at $78,000 after acquiring an additional 20,500 shares in the last quarter. Magnus Financial Group LLC boosted its stake in Checkpoint Therapeutics by 12.9% during the 3rd quarter. Magnus Financial Group LLC now owns 35,000 shares of the company's stock valued at $78,000 after purchasing an additional 4,000 shares during the last quarter. Finally, Choreo LLC increased its holdings in Checkpoint Therapeutics by 12.2% during the 2nd quarter. Choreo LLC now owns 65,002 shares of the company's stock worth $133,000 after purchasing an additional 7,080 shares in the last quarter. 22.00% of the stock is currently owned by institutional investors and hedge funds.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.